KRas G12D inhibitors

US11453683B1 · kind B1 · utility

Assignees

• Mirati Therapeutics, Inc. · US
• Array BioPharma, Inc. · US

Inventors

• Xiaolun Wang · San Diego, US
• Aaron Craig Burns · San Diego, US
• James Gail Christensen · San Diego, US
• John Michael Ketcham · San Diego, US
• John David Lawson · San Diego, US
• Matthew Arnold Marx · San Diego, US
• Christopher Ronald Smith · San Diego, US
• Shelley Allen · Boulder, US
• James F. Blake · Longmont, US
• Mark Joseph Chicarelli · Boulder, US
• Joshua Ryan Dahlke · Boulder, US
• Donghua Dai · Boulder, US
• Jay Bradford Fell · Boulder, US
• John P. Fischer · Boulder, US
• Macedonio J. Mejia · Denver, US
• Brad Newhouse · Boulder, US
• Phong X. Nguyen · Placentia, US
• Jacob Matthew O'Leary · Denver, US
• Spencer Pajk · Boulder, US
• Martha E. Rodriguez · Boulder, US
• Pavel Savechenkov · Boulder, US
• Tony P. Tang · Boulder, US
• Guy P.A. Vigers · Boulder, US
• Qian Zhao · Louisville, US
• Dean Russell Kahn · Boulder, US
• John Gaudino · Longmont, US
• Michael Christopher Hilton · Boulder, US

Key dates

• Filing date: Aug 27, 2020
• Grant date: Sep 27, 2022
• Expiry date: Oct 15, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.